Project Grant R44AR087317
Award Date 9/1/26
Completion Date 8/31/28
Dollars Obligated $996K
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Chicago, IL 60642, USA
Similar Awards
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded Duke University $377,506 on June 5, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to develop a chimeric antigen receptor T cell (CAR-T) therapy targeting inflammation and fibrosis in Duchenne muscular dystrophy. The research will evaluate CAR-T cells engineered to eliminate pro-inflammatory macrophages and fibrogenic fibro-adipogenic progenitors in the dystrophic muscle...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded the University of Arizona $578,565 on July 10, 2026, to investigate the role of skeletal myosin binding protein-C in distal arthrogryposis under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). Distal arthrogryposis is a genetic skeletal muscle disorder characterized by congenital joint contractures, muscle weakness, and reduced mobility with significant clinical morbidity. No...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded $151,040 to The University of Texas Southwestern Medical Center on April 15, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to develop muscle-optimized non-viral gene editors for Duchenne muscular dystrophy. The project addresses limitations in lipid nanoparticle (LNP) delivery of CRISPR gene editing to skeletal muscle by designing gene editors that improve myonuclear...
- The National Institutes of Health's National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded New York University School of Medicine $409,311.92 under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) from April 5, 2021 to January 25, 2022. The project grant funding supports research into the role of T follicular helper (TFH) cells in the pathogenesis of dermatomyositis, a severe inflammatory myopathy. Specifically, the award will fund studies to...
- The National Institutes of Health National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded the Board of Trustees of Illinois State University $544,734 on August 1, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to investigate smooth muscle pathology mechanisms in Duchenne muscular dystrophy. The project, running through July 31, 2029, uses C. elegans as a model system to characterize smooth muscle dysfunction associated with...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded the University of Arizona $375,381 on September 2, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to develop a small-molecule drug discovery platform targeting MYBPC1 mutations that cause distal arthrogryposis. The project addresses the absence of available therapeutics for distal arthrogryposis, a congenital muscle disorder affecting approximately 1 in 3,000 live births...
- The National Heart, Lung, and Blood Institute awarded Novomedix LLC $355,963 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and test novel small-molecule anti-fibrotic compounds for prevention and treatment of Duchenne muscular dystrophy cardiomyopathy. The project addresses cardiac complications in DMD patients, where improved respiratory support has extended survival into the second and third decade of life but exposed an unmet need for...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded the University of Florida $1.768 million on September 15, 2025, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to assess magnetic resonance measures of bioenergetics and microvascular function in Duchenne and Becker muscular dystrophy. The project evaluates whether MR-based measures of muscle energetics and blood vessel function can track disease progression and treatment...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded Biosensics LLC $314,362 under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) on September 1, 2026, to develop digital assessment tools for motor skills in infants and young boys with Duchenne muscular dystrophy using wearable sensors. The project addresses a critical clinical gap: current motor assessment methods (Bayley Scales of Infant and Toddler Development) cannot detect...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), part of the National Institutes of Health under the Department of Health and Human Services, awarded $585,012 to Massachusetts General Hospital on June 2, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The award funds research investigating the role of the C10ORF10/DEPP1 protein in skeletal muscle atrophy. The recipient will conduct three specific aims: defining the...